MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Don't miss out on this unique opportunity

ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.

Bolag anklagas för att ha mörkat förhöjd risk för deltagare i alzheimerstudier

Ett stort antal deltagare i de kliniska alzheimerstudierna av lecanemab och donanemab bar på en genvariant som gjorde att de löpte förhöjd risk för allvarliga b...

AI detects tumor disease – via voice recording

A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and in...

Tarmflorans betydelse för flera vanliga sjukdomar ska utforskas

Ett internationellt forskningsinitiativ, där Göteborgs universitet ingår, ska undersöka om tarmbakterier kan orsaka fetma, typ 2-diabetes och hjärt-kärlsjukdom.

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

Kriget i Ukraina ger bränsle åt totalt resistenta bakterier

Krigshärjade Ukraina lider inte bara av fientliga attacker från en utländsk angripare, utan också från hotet från en totalt resistent och smittsam bakterie.

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Optimize Courier SUPPLIERS (DISTRIBUTORS)

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

Siemens Healthineers köper del av Novartis

Tyska Siemens Healthineers planerar att köpa Novartis verksamhet AAA Diagnostics, som producerar radioaktiva kemikalier för bland annat cancerdiagnostik. Det ra...

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Life science trends 2025 – Neurology

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-...

Svensk vaccinutvecklare får 24 miljoner av brittiskt forskningsprogram

Abera Bioscience får upp till motsvarande cirka 24 miljoner kronor i finansiering från ett brittiskt program inriktat på vacciner som ska stoppa epidemier i låg...

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

A new giant among our microscopes

Two technologies in one machine.

Jätteaffär på gång inom konsumenthälsa – Sanofi i förhandlingar

Franska Sanofi kan vara på väg att släppa greppet om sin division inom konsumenthälsa, Opella, i vad som kan bli årets största affär inom den europeiska hälsobranschen.

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Improve Productivity and Accessibility with Award-winning Human-Centered Design

Enhance your workflow with integrated intelligence.